Check out the full NCCN guidelines by creating a FREE account at www.nccn.org
Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic
January 10th, 2023 (Version 2.2023) focused on male BRCA carriers:
› Consider annual mammograms (particularly in BRCA2 carriers) starting at age 50 or 10 years before the earliest male breast cancer in the family (whichever comes first)
February 13th, 2023 (Version 3.2023)
› To release the annual update of the discussions section, which is a tremendous source of background information, to provide information upon which the updates to the guidelines were based
Genetic/Familial High-Risk Assessment: Colorectal
December 7th, 2022 Update (Version 2.2022)
› Lynch Syndrome: No clear data exist to support surveillance for gastric, duodenal, and more distal small bowel cancer
› Familial Adenomatous Polyposis: Surveillance, after APC positive, bullet revised: High-quality colonoscopy (preferred) every 12 months beginning at age 10–15; explanation provided in footnote: Colonoscopy is preferred due to the possibility of missing early transverse colon and right-sided polyps when limiting to sigmoidoscopy. However, based on patient and family preference or clinical judgment, sigmoidoscopy may also be considered.
› Gene/Syndrome tables extensively revised and updated, specifically pages GENE-3 through GENE-19
Inherited Cancer Content in Other NCCN Guidelines (aside from the Genetic/Familial already listed)
› In the Genetics/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic guidelines, there is now a table added at the end of the guidelines to summarize inherited cancer content across ALL NCCN guidelines, including a live link to table of contents and name of section heading in table of contents with this content. Table on page 55 of 148 (starting on SUMM-1 page)